Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
EDITORIAL ARTICLE
Catastrophic antiphospholipid syndrome: 20 years of research work (1992–2012)
Online publication date: 2012-11-06
Reumatologia 2012;50(5):363-369
KEYWORDS
catastrophic antiphospholipid syndromeAsherson’s syndromeantiphospholipid antibodiesanticardiolipin antibodieslupus anticoagulantantiphospholipid syndrome
ABSTRACT
The catastrophic variant of the antiphospholipid syndrome (APS) is an uncommon but potentially life-threatening condition that needs high clinical awareness. Fortunately, less than 1% of patients with the APS develop this complication, but its potentially lethal outcome emphasizes its importance in clinical medicine today. A basic and sudden disturbance of the coagulation or fibrinolytic systems induced by the antiphospholipid antibodies (aPL) is highly probable in this group of patients, but precipitating factors remain unknown in most of them. The therapeutic connotation is that this may be corrected with the combination of anticoagulants plus glucocorticoids plus attempts at achieving a prompt reduction of aPL titer (i.e. plasma exchange and/or intravenous immunoglobulins).
REFERENCES (32)
1.
Asherson RA. The catastrophic antiphospholipid antibody syndrome. J Rheumatol 1992; 19: 508-512.
2.
Piette JC, Cervera R, Levy RA, et al. The catastrophic antiphospholipid syndrome – Asherson’s syndrome. Ann Med Interne (Paris) 2003; 154: 195-196.
3.
Asherson RA, Cervera R, Piette JC, et al. Catastrophic antibody syndrome. Clinical and laboratory features of 50 patients. Medicine (Baltimore) 1998; 77: 195-207.
4.
Asherson RA, Cervera R, Piette JC, et al. Catastrophic antiphospholipid syndrome: clues to the pathogenesis from a series of 80 patients. Medicine (Baltimore) 2001; 80: 355-377.
5.
Bucciarelli S, Espinosa G, Cervera R, et al. Mortality in the catastrophic antiphospholipid syndrome: causes of death and prognostic factors in a series of 250 patients. Arthritis Rheum 2006; 54: 2568-2576.
6.
Cervera R, Piette JC, Font J, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum 2002; 46: 1019-1027.
7.
Asherson RA, Cervera R, de Groot PG, et al. Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines. Lupus 2003; 12: 530-534.
8.
Cervera R, Font J, Gómez-Puerta JA, et al. Validation of the preliminary criteria for the classification of catastrophic antiphospholipid syndrome. Ann Rheum Dis 2005; 64: 1205-1209.
9.
Cervera R, Bucciarelli S, Plasín MA, et al. Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of a series of 280 patients from the “CAPS Registry”. J Autoimmun 2009; 32: 240-245.
10.
Espinosa G, Cervera R, Asherson RA. Catastrophic antiphospholipid syndrome and sepsis. A common link? J Rheumatol 2007; 34: 923-926.
11.
Cervera R, Font J, Tincani A, Boffa MC. V meeting of the European forum on antiphospholipid antibodies. Autoimmun Rev 2006; 5: 499-507.
12.
Asherson RA, Espinosa G, Menahem S, et al. Relapsing catastrophic antiphospholipid syndrome: report of three cases. Semin Arthritis Rheum 2008; 37: 366-372.
13.
Gómez-Puerta JA, Cervera R, Espinosa G, et al. Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases. Ann Rheum Dis 2007; 66: 740-746.
14.
Miesbach W, Asherson RA, Cervera R, et al. The role of malignancies in patients with catastrophic antiphospholipid (Asherson’s) syndrome. Clin Rheumatol 2007; 26: 2109-2114.
15.
Cervera R, Espinosa G, Cordero A, et al. Intestinal involvement secondary to the antiphospholipid syndrome (APS): clinical and immunologic characteristics of 97 patients: comparison of classic and catastrophic APS. Semin Arthritis Rheum 2007; 36: 287-296.
16.
Belmont HM, Abramson SB, Lie JT. Pathology and pathogenesis of vascular injury in systemic lupus erythematosus. Arthritis Rheum 1996; 39: 9-22.
17.
Bucciarelli S, Espinosa G, Asherson RA, et al. The acute respiratory distress syndrome in catastrophic antiphospholipid syndrome: analysis of a series of 47 patients. Ann Rheum Dis 2006; 65: 81-86.
18.
Asherson RA, Espinosa G, Cervera R, et al. Disseminated intravascular coagulation in catastrophic antiphospholipid syndrome: clinical and haematological characteristics of 23 patients. Ann Rheum Dis 2005; 64: 943-946.
19.
Ferrara DE, Liu X, Espinola RG, et al. Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model. Arthritis Rheum 2003; 48: 3272-3279.
20.
López-Pedrera C, Ruiz-Limón P, Aguirre MÁ, et al. Global effects of fluvastatin on the prothrombotic statins of patients with antiphospholipid syndrome. Ann Rheum Dis 2011; 70: 675-682.
21.
Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus 2008; 17: 50-55.
22.
Espinosa G, Cervera R. Recent trends in the management of antiphospholipid syndrome (Hughes syndrome). Drugs Today (Barc) 2010; 46: 39-47.
23.
Ketari Jamoussi S, Zaghdoudi I, Ben Dhaou B, et al. Catastrophic antiphospholipid syndrome and rituximab: a new report. Tunis Med 2009; 87: 699-702.
24.
Nageswara Rao AA, Arteaga GM, Reed AM, et al. Rituximab for successful management of probable pediatric catastrophic antiphospholipid syndrome. Pediatr Blood Cancer 2009; 52: 536-538.
25.
van Wissen S, Bastiaansen BA, Stroobants AK, et al. Catastrophic antiphospholipid syndrome mimicking a malignant pancreatic tumour – a case report. Lupus 2008; 17: 586-590.
26.
Manner H, Jung B, Tonassi L, et al. Successful treatment of catastrophic antiphospholipid antibody syndrome (CAPS) associated with splenic marginal-zone lymphoma with low-molecular weight heparin, rituximab and bendamustine. Am J Med Sci 2008; 335: 394-397.
27.
Haque W, Kadikoy H, Pacha O, et al. Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy. Rheumatol Int 2010; 30: 719-723.
28.
Iglesias-Jiménez E, Camacho-Lovillo M, Falcón-Neyra D, et al. Infant with probable catastrophic antiphospholipid syndrome successfully managed with rituximab. Pediatrics 2010; 125: e1523-1528.
29.
Rubenstein E, Arkfeld DG, Metyas S, et al. Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol 2006; 33: 355-357.
30.
Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010; 362: 1744-1745.
31.
Hillmen P, Young NS, Schubert J, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006; 355: 1233-1243.
32.
Locke JE, Magro CM, Singer AL, et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009; 9: 231-235.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
